Faruqi and Faruqui, LLP Logo
Share this page

Medivation, Inc. (MDVN)



Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Medivation, Inc.

Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Northern District of California, case no. 3:16-cv-05154, on behalf of shareholders of Medivation, Inc. (“Medivation” or the “Company”) (NasdaqGS:MDVN) who  held Medivation securities and have been harmed by Medivation’s and its board of directors’ (the “Board”) alleged violations of Sections 14(d)(4), 14(e), and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and SEC Rule 14d-9 in connection with the proposed acquisition (“Proposed Transaction”) of the Company by Pfizer, Inc.(“ Pfizer”).

On August 30, 2016, Montreal, Inc., a wholly-owned subsidiary of Pfizer, commenced a tender offer for Medivation shares scheduled to expire on September 27, 2016. If a sufficient number of Medivation shares are tendered, a second-step merger will be effectuated without a shareholder vote, and Montreal, Inc. will merge with and into Medivation, with Medivation continuing as a wholly-owned subsidiary of Pfizer.

Pursuant to the terms of the Merger Agreement, which was unanimously approved by the Board, Medivation shareholders stand to receive $81.50 per share in cash for each share they own. The complaint claims that this offer is inadequate in light of the Company’s intrinsic value and long-term prospects and alleges that the Schedule 14D-9 Solicitation/Recommendation Statement (the “14D-9”) provides materially incomplete and misleading information about the process leading up to the Board’s decision to approve the Proposed Transaction and the valuation analyses performed by the Board’s financial advisors, in violation of Sections 14(d)(4), 14(e), and 20(a) of the Exchange Act.

Take Action

If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from today.  Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.  If you wish to discuss this action, or have any questions concerning this notice or your rights or interests, please contact Nadeem Faruqi, Esq. either via e-mail at nfaruqi@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330 or James M. Wilson, Jr., Esq. at jwilson@faruqilaw.com.


Request Information

Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.

  • Company:
    Medivation, Inc. (MDVN)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Nadeem Faruqi
James M. Wilson, Jr.
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 09/09/2016

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.